ProQR Therapeutics Net Income From Continuing Ops Over Time
| PRQR Stock | USD 1.50 0.11 7.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ProQR Therapeutics Performance and ProQR Therapeutics Correlation. Can Biotechnology industry sustain growth momentum? Does ProQR have expansion opportunities? Factors like these will boost the valuation of ProQR Therapeutics. Anticipated expansion of ProQR directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ProQR Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
ProQR Therapeutics's market price often diverges from its book value, the accounting figure shown on ProQR's balance sheet. Smart investors calculate ProQR Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since ProQR Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ProQR Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProQR Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ProQR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare ProQR Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (3 M) | (18.6 M) | (14 M) | (23.8 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (17 M) | (17 M) | (17 M) | (17 M) | (11.1 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (10 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | 76.7 K | 76.7 K | 76.7 K | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.3 M) | 8.4 K | 9.6 K | 10.1 K |
ProQR Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| ProQR Therapeutics BV | PRQR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Zernikedreef 9, Leiden, |
| Exchange | NASDAQ Exchange |
USD 1.5
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.